- Home
- ISRG vs GILD Comparison
ISRG vs GILD Comparison
Compare ISRG & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | GILD |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5B | 187.5B |
| IPO Year | 1998 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ISRG | GILD |
|---|---|---|
| Price | $508.31 | $145.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $612.40 | $143.50 |
| AVG Volume (30 Days) | 1.9M | ★ 6.8M |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | 22.59 | ★ 1684.21 |
| EPS | ★ 7.87 | 6.78 |
| Revenue | $10,064,700,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $16.75 | $4.68 |
| Revenue Next Year | $13.85 | $5.81 |
| P/E Ratio | $64.25 | ★ $21.70 |
| Revenue Growth | ★ 20.51 | 9.98 |
| 52 Week Low | $425.27 | $95.30 |
| 52 Week High | $603.88 | $157.29 |
Technical Indicators
Market Signals| Indicator | ISRG | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 50.23 |
| Support Level | $498.17 | $108.90 |
| Resistance Level | $557.45 | $157.29 |
| Average True Range (ATR) | 11.59 | 4.02 |
| MACD | 4.31 | -1.61 |
| Stochastic Oscillator | 96.24 | 5.40 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).